Featured Chrome Extensions:

Casey IRACs are produced by an AI that analyzes the opinion’s content to construct its analysis. While we strive for accuracy, the output may not be flawless. For a complete and precise understanding, please refer to the linked opinions above.

Keywords

lawsuitappealsummary judgmentjudicial reviewrespondent
statutesummary judgmentjudicial reviewrespondent

Related Cases

Bruno v. United States, 472 F.Supp.3d 279
View Case »
People v. Frierson, 25 Cal.3d 142, 599 P.2d 587, 158 Cal.Rptr. 281
View Case »
Com. v. Aurick, 342 Pa. 282, 19 A.2d 920
View Case »
Bedell v. Commonwealth, Not Reported in S.W. Rptr., 2023 WL 3767435
View Case »
State v. Britson, 130 Ariz. 380, 636 P.2d 628
View Case »
Justia Law Link
LexisNexis Link
Westlaw Link
CourtListener Link
Oyez Link

Heckler v. Chaney, 470 U.S. 821, 105 S.Ct. 1649, 84 L.Ed.2d 714, 53 USLW 4385, 15 Envtl. L. Rep. 20,335

Facts

Respondent prison inmates, convicted of capital offenses and sentenced to death by lethal injection, petitioned the FDA to take enforcement actions against the use of certain drugs for executions, arguing that such use violated the FDCA. The FDA refused their request, stating that it had discretion not to interfere with state criminal justice systems. The inmates then filed a lawsuit in the District Court, which granted summary judgment for the FDA, leading to an appeal.

Respondent prison inmates were convicted of capital offenses and sentenced to death by lethal injection of drugs. They petitioned the Food and Drug Administration (FDA), alleging that use of the drugs for such a purpose violated the Federal Food, Drug, and Cosmetic Act (FDCA), and requesting that the FDA take various enforcement actions to prevent those violations.

Issue

The main legal issue was whether the FDA's decision not to undertake enforcement actions regarding the use of drugs for lethal injections was subject to judicial review under the Administrative Procedure Act.

This case presents the question of the extent to which a decision of an administrative agency to exercise its “discretion” not to undertake certain enforcement actions is subject to judicial review under the Administrative Procedure Act, 5 U.S.C. § 501 et seq. (APA).

Rule

The Supreme Court held that decisions by an agency not to take enforcement action are generally presumed unreviewable under the Administrative Procedure Act unless Congress has provided meaningful standards for judicial review.

Under § 701(a)(2), judicial review of an administrative agency's decision is not to be had if the statute in question is drawn so that a court would have no meaningful standard against which to judge the agency's exercise of discretion.

Analysis

The Court analyzed the FDA's refusal to act and determined that the presumption of unreviewability applied. It found that the FDCA did not provide sufficient standards to challenge the FDA's discretion, and thus the agency's decision was not subject to judicial review. The Court emphasized that the FDA's enforcement decisions are traditionally committed to agency discretion.

The presumption that agency decisions not to institute enforcement proceedings are unreviewable under § 701(a)(2) is not overcome by the enforcement provisions of the FDCA.

Conclusion

The Supreme Court reversed the Court of Appeals' decision, concluding that the FDA's refusal to take enforcement action regarding the drugs used for lethal injections was not subject to judicial review under the APA.

Held: The FDA's decision not to take the enforcement actions requested by respondents was not subject to review under the APA.

Who won?

The FDA prevailed in the case because the Supreme Court found that its decision not to enforce was unreviewable under the Administrative Procedure Act.

The District Court granted summary judgment for petitioner, holding that nothing in the FDCA indicated an intent to circumscribe the FDA's enforcement discretion or to make it reviewable.

You must be